S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.28 (-0.33%)
AAPL   114.21 (-0.65%)
MSFT   207.77 (-0.80%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,148.15 (-0.82%)
TSLA   419.72 (-0.35%)
NVDA   529.99 (+1.65%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.55 (+1.67%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.28 (-0.33%)
AAPL   114.21 (-0.65%)
MSFT   207.77 (-0.80%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,148.15 (-0.82%)
TSLA   419.72 (-0.35%)
NVDA   529.99 (+1.65%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.55 (+1.67%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.28 (-0.33%)
AAPL   114.21 (-0.65%)
MSFT   207.77 (-0.80%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,148.15 (-0.82%)
TSLA   419.72 (-0.35%)
NVDA   529.99 (+1.65%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.55 (+1.67%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.28 (-0.33%)
AAPL   114.21 (-0.65%)
MSFT   207.77 (-0.80%)
FB   261.90 (+1.98%)
GOOGL   1,467.99 (+0.64%)
AMZN   3,148.15 (-0.82%)
TSLA   419.72 (-0.35%)
NVDA   529.99 (+1.65%)
BABA   276.93 (+0.33%)
CGC   14.50 (+2.04%)
GE   6.12 (-1.29%)
MU   50.55 (+1.67%)
AMD   82.20 (+3.42%)
T   28.30 (-0.28%)
F   6.60 (-1.35%)
ACB   4.68 (-2.09%)
GILD   62.09 (-1.21%)
NFLX   494.30 (+0.74%)
DIS   125.40 (-0.47%)
BA   163.60 (-1.49%)
BAC   23.77 (-1.33%)
Log in
NASDAQ:SLNO

Soleno Therapeutics Stock Forecast, Price & News

$2.07
+0.21 (+11.29 %)
(As of 09/29/2020 04:31 PM ET)
Add
Compare
Today's Range
$1.90
Now: $2.07
$2.09
50-Day Range
$1.79
MA: $1.95
$2.16
52-Week Range
$1.18
Now: $2.07
$4.39
Volume788,978 shs
Average Volume542,349 shs
Market Capitalization$164.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More
Soleno Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Employees9
Market Cap$164.76 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$2.07
+0.21 (+11.29 %)
(As of 09/29/2020 04:31 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

How has Soleno Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SLNO stock has decreased by 17.5% and is now trading at $2.07.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Soleno Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Soleno Therapeutics
.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Soleno Therapeutics
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.16) EPS for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.05.
View Soleno Therapeutics' earnings history
.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Shares of Soleno Therapeutics reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

4 equities research analysts have issued 1-year target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $9.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price.
View analysts' price targets for Soleno Therapeutics
.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 1,390,000 shares, a drop of 10.3% from the August 31st total of 1,550,000 shares. Based on an average daily volume of 831,900 shares, the short-interest ratio is currently 1.7 days.
View Soleno Therapeutics' Short Interest
.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Opko Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $2.07.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $164.76 million. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.